Presentazione a cura della Dottoressa Francesca Galeazzi - "Malattia da reflussogastroesofageo e infezione da Helicobacter Pylori: old topics?" - Roma 11/05/2019
Kudos To You: Learning your Kudo Pit Patterns and Paris Polyp ClassificationsPatricia Raymond
We've told patients that we won't know about their polyps until after the pathology report is back; turns out that's not precisely true. Today's excellence in optics provides an accurate instantaneous assessment of the histology of colon polyps which may help in decision making during colonoscopy.
Did you know that if a polyp has a type 5 Kudo pit pattern, 50% were invasive cancers to the submucosal layer? What is it about that scary polyp that raises your hackles? Join us in this highly interactive session where we'll learn Kudo pit patterns as well as Paris polyp classifications to elevate your GI procedure reporting and your patient care.
Describe the emerging evidence supporting the primary role of Kudo Pit Patterns in visual inspection of in situ polyps, and demonstrate your ability to identify the patterns
Authentication of Kudo Pits
Pits and their risks
Images of Kudo pits
Quiz of Kudo Pits
Discuss the potential and shortcomings of the Paris Polyp Classification, and demonstrate an ability to classify the polyp shape
Polyp shapes and and their risks (pedunculated, elevated, depressed)
Images of polyps for Paris classification
Polyps and their risks
Quiz of polyp shapes
Concerns regarding interobserver variability
review of literature for transjugular intrahepatic portosystemic shunt placement and balloon occluded retrograde transvenous obliteration in management of patients with varices hemorrhage
Kudos To You: Learning your Kudo Pit Patterns and Paris Polyp ClassificationsPatricia Raymond
We've told patients that we won't know about their polyps until after the pathology report is back; turns out that's not precisely true. Today's excellence in optics provides an accurate instantaneous assessment of the histology of colon polyps which may help in decision making during colonoscopy.
Did you know that if a polyp has a type 5 Kudo pit pattern, 50% were invasive cancers to the submucosal layer? What is it about that scary polyp that raises your hackles? Join us in this highly interactive session where we'll learn Kudo pit patterns as well as Paris polyp classifications to elevate your GI procedure reporting and your patient care.
Describe the emerging evidence supporting the primary role of Kudo Pit Patterns in visual inspection of in situ polyps, and demonstrate your ability to identify the patterns
Authentication of Kudo Pits
Pits and their risks
Images of Kudo pits
Quiz of Kudo Pits
Discuss the potential and shortcomings of the Paris Polyp Classification, and demonstrate an ability to classify the polyp shape
Polyp shapes and and their risks (pedunculated, elevated, depressed)
Images of polyps for Paris classification
Polyps and their risks
Quiz of polyp shapes
Concerns regarding interobserver variability
review of literature for transjugular intrahepatic portosystemic shunt placement and balloon occluded retrograde transvenous obliteration in management of patients with varices hemorrhage
Chair, Brendon M. Stiles, MD, and Helena A. Yu, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC activity titled “Precision Decisions in Multimodal Management of Early-Stage NSCLC: Integrating EGFR-Targeted Therapy in Perioperative Settings.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3SWB9gl. CME/MOC credit will be available until October 29, 2023.
Presented by the Johns Hopkins University School of Medicine and
produced in collaboration with the Institute for Medical Education & Research (IMER).
Review a downloadable slide deck by, covering the most clinically relevant new data reported from Expert Video Viewpoints on Castration-Resistant Prostate Cancer: Care Across the Continuum by:
Emmanuel Antonarakis, MBBCh
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
Leonard G. Gomella, MD, FACS
Thomas Jefferson University
Jefferson Kimmel Cancer Center
A. Oliver Sartor, MD
Tulane University School of Medicine
Target Audience
Medical oncologists, urologists, radiation oncologists, and other healthcare professionals involved in the treatment of patients with castration-resistant prostate cancer (CRPC). There are no prerequisites.
Activity Overview
In this video, a panel of expert thought leaders will discuss the optimal management and emerging agents across the CRPC treatment continuum. Topics will include identification and initial treatment of CRPC, metastatic CRPC progression, future novel treatment for CRPC patients, and expert perspectives on case examples to decipher optimal treatment of CRPC.
Slide Deck Disclaimer
This slide deck in its original and unaltered format is for educational purposes and is current as of December 2011. All materials contained herein reflect the views of the faculty, and not those of IMER, the CME provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at your own risk, and readers should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
Usage Rights
This slide deck is provided for educational purposes and individual slides may be used for personal, non-commercial presentations only if the content and references remain unchanged. No part of this slide deck may be published in print or electronically as a promotional or certified educational activity without prior written permission from IMER. Additional terms may apply. See Terms of Service on IMERonline.com for details.
Ulcerative Colitis: Applying Guidelines in PracticeDevi Seal
This presentation developed was by David Rubin, MD, Millie Long, MD, MPH, and Anita Afzali, MD, MPH, for a CME activity titled, Ulcerative Colitis: Applying Guidelines in Practice
Recent Update on Management of Ulcerative ColitisDr Amit Dangi
Recent update on the surgical and medical management of ulcerative colitis, including various controversies regarding IPAA and recent medical management incorporating the role of biologicals
Chair, Brendon M. Stiles, MD, and Helena A. Yu, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC activity titled “Precision Decisions in Multimodal Management of Early-Stage NSCLC: Integrating EGFR-Targeted Therapy in Perioperative Settings.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3SWB9gl. CME/MOC credit will be available until October 29, 2023.
Presented by the Johns Hopkins University School of Medicine and
produced in collaboration with the Institute for Medical Education & Research (IMER).
Review a downloadable slide deck by, covering the most clinically relevant new data reported from Expert Video Viewpoints on Castration-Resistant Prostate Cancer: Care Across the Continuum by:
Emmanuel Antonarakis, MBBCh
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
Leonard G. Gomella, MD, FACS
Thomas Jefferson University
Jefferson Kimmel Cancer Center
A. Oliver Sartor, MD
Tulane University School of Medicine
Target Audience
Medical oncologists, urologists, radiation oncologists, and other healthcare professionals involved in the treatment of patients with castration-resistant prostate cancer (CRPC). There are no prerequisites.
Activity Overview
In this video, a panel of expert thought leaders will discuss the optimal management and emerging agents across the CRPC treatment continuum. Topics will include identification and initial treatment of CRPC, metastatic CRPC progression, future novel treatment for CRPC patients, and expert perspectives on case examples to decipher optimal treatment of CRPC.
Slide Deck Disclaimer
This slide deck in its original and unaltered format is for educational purposes and is current as of December 2011. All materials contained herein reflect the views of the faculty, and not those of IMER, the CME provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at your own risk, and readers should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
Usage Rights
This slide deck is provided for educational purposes and individual slides may be used for personal, non-commercial presentations only if the content and references remain unchanged. No part of this slide deck may be published in print or electronically as a promotional or certified educational activity without prior written permission from IMER. Additional terms may apply. See Terms of Service on IMERonline.com for details.
Ulcerative Colitis: Applying Guidelines in PracticeDevi Seal
This presentation developed was by David Rubin, MD, Millie Long, MD, MPH, and Anita Afzali, MD, MPH, for a CME activity titled, Ulcerative Colitis: Applying Guidelines in Practice
Recent Update on Management of Ulcerative ColitisDr Amit Dangi
Recent update on the surgical and medical management of ulcerative colitis, including various controversies regarding IPAA and recent medical management incorporating the role of biologicals
Slide per la gestione del sondino nasogastrico ed orogastrico. Slide approntate da Stefano Bambi per lezioni universitarie nei corsi di laurea triennale in infermieristica e medicina
I meccanismi del danno gastrico e la patologia H. Pylori correlataASMaD
Presentazione a cura del Dottor Vincenzo De Francesco - "Malattia da reflussogastroesofageo e infezione da Helicobacter Pylori: old topics?" - Roma 11/05/2019
Presentazione a cura del Professor Enrico Corazziari - "Malattia da reflussogastroesofageo e infezione da Helicobacter Pylori: old topics?" - Roma 11/05/2019
Cambiamenti di popolazione e flussi migratori: cambiano anche le malattie met...ASMaD
Presentazione a cura della Dottoressa Migneco Maria Giuseppina - "Incontri endocrinologici AME LAzio - L'endocrinologia nel SSN: prospettive e nuove problematiche" - Roma 17/12/2018
Tiroide: chi decide quale intervento e per chi?ASMaD
Presentazione a cura del Dottor Bellotti Carlo - "Incontri endocrinologici AME LAzio - L'endocrinologia nel SSN: prospettive e nuove problematiche" - Roma 17/12/2018
Tiroide: Integrazione tra elementi nutriacetici e farmacologia: utile o inutile?ASMaD
Presentazione a cura del Dottor Roberto Cesareo - "Incontri endocrinologici AME LAzio - L'endocrinologia nel SSN: prospettive e nuove problematiche" - Roma 17/12/2018
L'ecografia tiroidea: strumento cruciale nella gestione clinica?ASMaD
Presentazione a cura del Dottor Guglielmi Rinaldo - "Incontri endocrinologici AME LAzio - L'endocrinologia nel SSN: prospettive e nuove problematiche" - Roma 17/12/2018
Il chirurgo e la tiroide oggi un rapporto in crisi?ASMaD
Presentazione a cura del Dottor Luca Piantoni e del Dottor Francesco Pedicini - "TIROIDE 2018 Nuovi approcci diagnostici e terapeutici" - Roma 24/11/2018
Presentazione a cura della Dottoressa Rosella Pasqualoni e del dottor Gregorio Reda - "TIROIDE 2018 Nuovi approcci diagnostici e terapeutici" - Roma 24/11/2018
Presentazione a cura della Dottoressa Stefania Falcone e del Dottor Orazio Falla - "TIROIDE 2018 Nuovi approcci diagnostici e terapeutici" - Roma 24/11/2018
2. Vakil N et al Am J Gastroenterol 2006
GERD is a condition which develops when the reflux of stomach
content causes troublesome symptoms and/or complications
7. pH
Impedance
pH monitoring MII + pH monitoring
Acid + +
NON acid Blind +
Acid re-reflux Blind +
GAS Blind +
Height 1-2 levels 6 levels
Chem clearance + +
Bolus clearance Blind +
Postprandial GER 50% 100%
Savarino E et al Ann N Y Acad Sci. 2013
8. NERD: sottoclassificazione
(pH-impedenzometria)
Non Erosive Reflux Disease
Esposizione all’acido patologica
(42%)
Esofago ipersensibile
all’acido
pH normale
Associazione con sintomi
15-20 %
Esofago ipersensibile
a non acido
pH normale
Associazione con sintomi
12-17%
Pirosi funzionale
pH normale
No associazione con sintomi
(26%)
Mod da: Savarino E et al, Am J Gastroenterol 2008
9. NERD: sottoclassificazione
(pH-impedenzometria)
Non Erosive Reflux Disease
Esposizione all’acido patologica
(42%)
Esofago ipersensibile
all’acido
pH normale
Associazione con sintomi
15-20 %
Esofago ipersensibile
a non acido
pH normale
Associazione con sintomi
12-17%
Pirosi funzionale
pH normale
No associazione con sintomi
(26%)
Mod da: Savarino E et al, Am J Gastroenterol 2008
15. Chang AB et al, Cochrane Database Syst Rev 2011
Tosse-reflusso
16. Sifrim D et al, Gut 2005
Herregods TVK et al, Dis Esophagus 2018
129 pz tosse cronica:
25.5% relazione reflusso tosse
presenza di sintomi tipici e esposizione patologica all’acido
17. • Segni laringite posteriore in > 80%
asintomatici
• MII-pH: diagnosi MRGE < 40% dei pazienti
con LPR
De Bortoli N et al, W J Gastroenterol 2012
Sakin YS et ak, United European Gastroenterol J. 2017
Sintomi ORL
18.
19.
20. • Paziente a digiuno
• Sospensione PPI 7-15 gg
• Preceduta da Manometria (individuazione SEI)
• Sensore pH posizionato 5 cm prossimalmente allo SEI
• Diario dei sintomi, pasti, cambi posizione (orto/clino)
• Durata 24 ore
22. ImpedancepHpHpHpHpH
5 cm pross SEI
20 cm pross SEI
5 cm pross SEI
20 cm pross SEI
0
9
0
10
0
10
9
Savarino EV et al, Nat Med Rew 2017
23. Acid Exposure Time (Totale, ortostatismo, clinostatismo):
fisiologico < 4%, patologico >6%
DeMeester score: AET tot, supino, ortostatismo, durata reflusso più lungo,
reflussi > 5 min, numero totale reflussi
Frazzoni M et al, Clin Gastroenterol Hepatol. 2016
Martinucci I et al, Neurogastroenterol Motil. 2016
Frazzoni L et al, Neurogastroenterol Motil. 2017
Si reflusso
si sintomo
No reflusso
si sintomo
Si reflusso
No sintomo
No reflusso
no sintomo
SYMPTOM ASSOCIATION PROBABILITY (SAP) (POS > 95%)
Periodi di 2 min: Fisher Test
Numero di episodi sintomatici correlati a reflusso
Numero totale di episodi sintomatici
X 100
SYMPTOM INDEX (SI) (POS > 50%)
Numero di episodi di reflusso associati ai sintomi
Numero totale di reflussi
X 100
SYMPTOM SENSITIVITY INDEX (SI)
24. Postreflex swallow-induced peristaltic wave index (PSPW):
Peristalsi indotta da reflusso (nei 30 sec successivi), ridotta in MRGE vs controlli
Mean nocturnal baseline impedance (MNBI):
Indice di integrità mucosa. Ridotta MNBI relata a esposizione all‘ acido
Frazzoni M et al, Clin Gastroenterol Hepatol. 2016
Martinucci I et al, Neurogastroenterol Motil. 2016
Frazzoni M et al, Dig Dis Sci 2017
Frazzoni L et al, Neurogastroenterol Motil. 2017
25.
26. • MRGE resistente a terapia
• Documentazione MRGE in sintomi
atipici
• Studio prechirurgico
• Diagnosi pirosi funzionale, sdr
ruminazione
Follow up post chirurgia e
trattamento acalasia
Savarino EV et al, Nat Med Rew 2017
28. • Valutare presenza e contenuto del reflusso
• Stabilire associazione sintomo-reflusso
• Dopo esame endoscopico e terapia con antisecretori
• Da eseguire in associazione a Manometria esofagea, generalmente dopo
sospensione degli antisecretori